Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human IL-2 mutein with higher antitumor efficacy than wild type IL-2.

Journal of immunology (Baltimore, Md. : 1950) - 15 Jun 2013

Carmenate Tania, Pacios Anabel, Enamorado Michel, Moreno Ernesto, Garcia-Martínez Karina, Fuente Dasha, León Kalet

Abstract excerpt

IL-2 has been used for the treatment of melanoma and renal cell carcinoma, but this therapy has limited efficacy and severe toxicity. Currently, it is assumed that part of the limited efficacy is due to the IL-2-driven preferential expansion of regulatory T cells, which dampen the antitumor immunity. In this study, we characterize a human IL-2 mutant with higher antitumor efficacy and lower toxicity than wild...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Flow Cytometry
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-2

Share to Melanoma

Share to Mice, Inbred BALB C

Share to Models, Theoretical

Share to Neoplasms, Experimental

Share to Protein Structure, Quaternary

Source

Identifiers

PMID: 23677467
DOI: 10.4049/jimmunol.1201895

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human IL-2 mutein with higher antitumor efficacy than wild type IL-2.PMID 23677467Read ↗

The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8+ T lymphocyte/Treg cell balance.Semantic proximity Read ↗

A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo.Semantic proximity Read ↗

Insights into the binding recognition and computational design of IL-2 muteins with enhanced predicted binding affinity to the IL-2 receptor α.Semantic proximity Read ↗

Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.Semantic proximity Read ↗

Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.Semantic proximity Read ↗

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity Read ↗

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategiesSemantic proximity Read ↗

Differentiating PD-1+ stem-like CD8 T cells towards distinct effectors with enhanced therapeutic potential by an engineered IL-2 cis-targeted to PD-1Semantic proximity Read ↗

New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseasesSemantic proximity Read ↗

IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.Semantic proximity Read ↗

IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy.Semantic proximity Read ↗

Regulatory T cell expansion by a highly CD25-dependent IL-2 mutein arrests ongoing autoimmunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.